http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Bevacizumab associated diaphragm rupture in patients with ovarian cancer
( Mi Hyeng Yim ),( Ji Eun Byun ),( Ye Jin Jo ),( Hyeng In Ha ),( Hwi Gon Kim ),( Yong Jin Na ),( Yong Jung Song ) 대한산부인과학회 2022 대한산부인과학회 학술대회 Vol.108 No.-
Bevacizumab is an angiogenesis inhibitor used for adjuvant chemotherapy and maintenance therapy after cytoreductive surgery for advanced ovarian cancer patients. Various adverse effects are encountered in the treatment of bevacizumab, which include gastrointestinal perforation, delayed wound healing, proteinuria, hypertension, congestive heart failure, nasal septal fistula. However, bevacizumab associated diaphragm rupture is a rare entity. We herein report a case of diaphragm rupture, which is the first reported complication of bevacizumab in ovarian cancer to our knowledge. A 54-year-old woman was treated with cytoreductive surgery for advanced ovarian cancer, followed by 6 cycles of paclitaxel and carboplatin combined with 5 cycles of bevacizumab, because largest diameter of residual disease was 1.5 cm. The response evaluation of adjuvant chemotherapy was complete remission. After 1 cycle of bevacizumab maintenance, she visited the emergency room with uncontrolled epigastric and chest pain. Abdomen computed tomography revealed diaphragmatic hernia with stomach herniation by diaphragm rupture. Diaphragmatic hernia was repaired by thoracic surgeon. Diaphragmatic rupture is a serious complication that may occur during the use of bevacizumab in the treatment of ovarian cancer.